Orphan Drugs

(asked on 29th January 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the Office of Health Economics Report, Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries, published in March 2017, what steps he is taking to develop the Highly Specialised Technology appraisal process at NICE.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 6th February 2018

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes it uses in the development of its guidance and recommendations, including through its Highly Specialised Technologies (HST) programme. NICE periodically reviews its methods and processes to ensure that they remain fit for purpose for the National Health Service in England and introduced changes to its methods for the evaluation of technologies through its HST programme in April 2017 following a public consultation.

Reticulating Splines